Abstract
Background: Metformin (MF) is an antidiabetic drug that belongs to class III of the biopharmaceutical classification system (BCS) characterized by high solubility and low permeability.
Objective: The study aimed to prepare metformin as nanostructured lipid carriers (MF-NLCs) to control the drug release and enhance its permeability through the biological membrane.
Methods: 22 full factorial design was used to make the design of MF-NLCs formulations. MFNLCs were prepared by hot-melt homogenization-ultra sonication technique using beeswax as solid lipid in the presence of liquid lipid (either capryol 90 or oleic acid) and surfactant (either poloxamer 188 or tween 80).
Results: The entrapment efficiency (EE%) of MF-NLCs was ranged from 85.2±2.5 to 96.5±1.8%. The particle size was in the nanoscale (134.6±4.1 to 264.1±4.6 nm). The value of zeta potential has a negative value ranged from -25.6±1.1 to -39.4±0.9 mV. The PDI value was in the range of 0.253±0.01 to 0.496±0.02. The cumulative drug release was calculated for MF-NLCs and it was found that Q12h ranged from 90.5±1.7% for MF-NLC1 to 99.3±2.8 for MF-NLC4. Infra-red (IR) spectroscopy and differential scanning calorimetry (DSC) studies revealed the compatibility of the drug with other ingredients. MF-NLC4 was found to be the optimized formulation with the best responses.
Conclusion: 22 full factorial design succeed to obtain an optimized formulation which controls the drug release and increases the drug penetration.
Keywords: Metformin (MF), nanostructured lipid carrier (NLCs), bees wax, optimization, permeability, entrapment efficiency (EE%), drug release.
[http://dx.doi.org/10.1021/jm900274q]
[http://dx.doi.org/10.1038/nrendo.2011.138]
[http://dx.doi.org/10.1007/s00125-017-4342-z]
[http://dx.doi.org/10.2337/diabetes.55.03.06.db05-0934]
[http://dx.doi.org/10.2337/diacare.13.6.696]
[http://dx.doi.org/10.1016/S0889-8529(05)70265-6]
[http://dx.doi.org/10.1186/cc7137]
[http://dx.doi.org/10.3109/03639045.2012.662503]
[http://dx.doi.org/10.1208/s12249-018-1085-1]
[http://dx.doi.org/10.1016/j.ijbiomac.2018.04.023]
[http://dx.doi.org/10.1007/s11094-019-02017-9]
[http://dx.doi.org/10.2174/187221013804484827]
[http://dx.doi.org/10.1007/s40005-013-0087-y]
[http://dx.doi.org/10.1016/j.ijpharm.2019.118838]
[http://dx.doi.org/10.1016/j.colsurfa.2007.08.005]
[http://dx.doi.org/10.1080/10717544.2019.1689313]
[http://dx.doi.org/10.1080/08982104.2019.1614055]
[http://dx.doi.org/10.1016/j.ijpharm.2020.119033]
[http://dx.doi.org/10.2174/2210303109666190717155731]
[http://dx.doi.org/10.1166/jbns.2014.1231]
[http://dx.doi.org/10.2307/3001821]
[http://dx.doi.org/10.3390/molecules24213971]
[http://dx.doi.org/10.7324/JAPS.2016.60903]
[http://dx.doi.org/10.2147/IJN.S144615]
[http://dx.doi.org/10.3390/pharmaceutics12060572]
[http://dx.doi.org/10.3390/molecules25030685]
[http://dx.doi.org/10.3390/antiox8080272]
[http://dx.doi.org/10.1016/j.ijbiomac.2017.04.098]
[http://dx.doi.org/10.1208/s12249-018-1283-x]
[http://dx.doi.org/10.1208/s12249-019-1597-3]
[http://dx.doi.org/10.3390/pharmaceutics11060284]
[http://dx.doi.org/10.1007/s40005-017-0342-8]
[http://dx.doi.org/10.1016/j.chemphyslip.2007.06.213]
[http://dx.doi.org/10.1080/10717544.2018.1529209]
[http://dx.doi.org/10.1016/j.jcis.2017.07.008]
[http://dx.doi.org/10.3390/pharmaceutics12040300]
[http://dx.doi.org/10.3390/molecules22101752]
[http://dx.doi.org/10.3390/scipharm85030025]
[http://dx.doi.org/10.1002/ejlt.201900082]
[http://dx.doi.org/10.22159/ajpcr.2018.v11i8.26444]
[http://dx.doi.org/10.1007/s10973-018-7072-7]
[http://dx.doi.org/10.1016/j.foodchem.2017.10.010]
[http://dx.doi.org/10.1080/03639045.2019.1569023]
![Wayfinder Image](/images/wayfinder.jpg)